子宮内二分脊椎の世界市場レポート 2025年

子宮内二分脊椎の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.2％で37億7,000万米ドルに成長します。予測期間中に予測される成長は、出生前診断と治療に対する意識の高まり、低侵襲手技の採用拡大、政府の取り組みと資金提供の増加、新興市場におけるヘルスケアインフラの拡大、胎児手術専門センターの増加などに起因すると考えられます。この期間の主な動向としては、出生前スクリーニングと診断の進歩、低侵襲手術手技の技術革新、胎児手術用生体材料の開発、羊水ベースの治療法の革新、胎児の発育をサポートする人工子宮技術の採用などが挙げられます。

ヘルスケア施設の成長が子宮内二分脊椎市場の拡大を牽引すると予想されます。ヘルスケア施設とは、効果的な医療サービスを提供するために必要不可欠なインフラ、システム、リソースを指します。ヘルスケアインフラの拡大は、主に遠隔医療、ロボット手術、AI主導型診断などの医療技術の進歩に起因しており、これらすべては、患者の転帰と効率を高めるために、最新の施設、特殊な機器、改善された医療提供システムを必要とします。これらのヘルスケア施設は、エビデンスに基づいた治療法、熟練した医療従事者、革新的な治療オプションへのアクセスを確保することで、子宮内二分脊椎をサポートし、これらすべてが患者の治療結果と生活の質を向上させる。例えば、米国を拠点とする非営利団体である米国病院協会（American Hospital Association）の報告によると、米国の病院総数は2024年には6,120に達し、2022年の6,093から増加しています。このようなヘルスケアインフラの成長は、子宮内二分脊椎市場の開拓に貢献しています。

子宮内二分脊椎市場で事業を展開する企業は、胎児への介入に高度な画像診断や低侵襲技術を取り入れた手術センターなど、革新的なセンターの設立に注力しています。手術センターは、入院の必要性をなくし、外科手術を外来で行う専門施設です。例えば、2025年1月、インドにあるワディア病院は、開放性二分脊椎に対する胎児手術を提供するセンターを開設しました。この施設では、最先端の手術手技と集学的アプローチを統合し、早期介入を可能にすることで、合併症を減らし、この疾患に罹患した乳児の長期転帰を改善することができます。このセンターは、手術の正確さと質の高い患者ケアを重視し、開放性二分脊椎の課題に取り組む家族に希望を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の子宮内二分脊椎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の子宮内二分脊椎市場：成長率分析
• 世界の子宮内二分脊椎市場の実績：規模と成長, 2019-2024
• 世界の子宮内二分脊椎市場の予測：規模と成長, 2024-2029, 2034F
• 世界の子宮内二分脊椎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の子宮内二分脊椎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脊髄髄膜瘤
• 髄膜瘤
• オクルタ
• 世界の子宮内二分脊椎市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 超音波
• 磁気共鳴画像法（MRI）
• 羊水穿刺
• 世界の子宮内二分脊椎市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 産後手術
• 薬物管理
• 世界の子宮内二分脊椎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 世界の子宮内二分脊椎市場：タイプ別サブセグメンテーション、脊髄髄膜瘤、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 開放性脊髄髄膜瘤
• 閉鎖性脊髄髄膜瘤
• 腰仙部脊髄髄膜瘤
• 胸部脊髄髄膜瘤
• 頸部脊髄髄膜瘤
• 世界の子宮内二分脊椎市場：タイプ別サブセグメンテーション、髄膜瘤、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 頭蓋髄膜瘤
• 脊髄髄膜瘤
• 後頭髄膜瘤
• 前頭髄膜瘤
• 壁側髄膜瘤
• 世界の子宮内二分脊椎市場：タイプ別サブセグメンテーション、オクルタ、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腰仙骨二分脊椎オクルタ
• 仙骨二分脊椎オクルタ
• 孤立性二分脊椎オクルタ
• 複雑性二分脊椎オクルタ
• 索状症候群関連オクルタ

第7章 地域別・国別分析

• 世界の子宮内二分脊椎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の子宮内二分脊椎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 子宮内二分脊椎市場：競合情勢
• 子宮内二分脊椎市場：企業プロファイル
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • GE HealthCare Overview, Products and Services, Strategy and Financial Analysis
  • UC San Francisco Overview, Products and Services, Strategy and Financial Analysis
  • Children's Health Overview, Products and Services, Strategy and Financial Analysis
  • Memorial Hermann Health System Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Oregon Health & Science University
• Seattle Children's
• Texas Children's
• Children's Hospital of Philadelphia
• UW Health
• UC Davis
• UCSF Health
• Burjeel Hospital
• UT Physicians
• Thieme Group
• Riley Children's Health
• Yale Medicine
• Focused Ultrasound Foundation
• Petals Health
• Brown University Health

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 子宮内二分脊椎市場2029：新たな機会を提供する国
• 子宮内二分脊椎市場2029：新たな機会を提供するセグメント
• 子宮内二分脊椎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Spina bifida in-utero refers to a prenatal surgical procedure aimed at repairing spina bifida, a neural tube defect in which the spine and spinal cord fail to develop properly. Performed before birth, this surgery helps reduce complications such as hydrocephalus, enhances mobility, and improves neurological outcomes. By closing the defect early, it protects the exposed spinal cord from further damage, ultimately improving the child's quality of life compared to postnatal repair.

The primary types of spina bifida in-utero include myelomeningocele, meningocele, and occulta. Myelomeningocele is the most severe form, characterized by the protrusion of the spinal cord and meninges through an opening in the spine. Diagnosis methods include ultrasound, magnetic resonance imaging (MRI), and amniocentesis. Treatment options consist of in-utero surgery, postnatal surgery, and medication management. These interventions are utilized in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgical centers.

The spina bifida in-utero market research report is one of a series of new reports from The Business Research Company that provides spina bifida in-utero market statistics, including spina bifida in-utero industry global market size, regional shares, competitors with a spina bifida in-utero market share, detailed spina bifida in-utero market segments, market trends and opportunities, and any further data you may need to thrive in the spina bifida in-utero industry. This spina bifida in-utero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spina bifida in utero market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to the rising prevalence of spina bifida, increased awareness of fetal surgery, higher maternal age and associated pregnancy risks, growing healthcare expenditures, and advancements in research and development within fetal medicine.

The spina bifida in utero market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The projected growth during the forecast period can be attributed to rising awareness of prenatal diagnosis and treatment, greater adoption of minimally invasive procedures, increased government initiatives and funding, the expansion of healthcare infrastructure in emerging markets, and the growing number of specialized fetal surgery centers. Key trends for this period include advancements in prenatal screening and diagnostics, technological innovations in minimally invasive surgical techniques, the development of biomaterials for fetal surgery, innovations in amniotic fluid-based therapies, and the adoption of artificial womb technology to support fetal development.

The growth of healthcare facilities is expected to drive the expansion of the spina bifida in-utero market. Healthcare facilities refer to the essential infrastructure, systems, and resources required to provide effective medical services. The expansion of healthcare infrastructure is primarily attributed to advancements in medical technology, such as telemedicine, robotic surgery, and AI-driven diagnostics, all of which require updated facilities, specialized equipment, and improved healthcare delivery systems to enhance patient outcomes and efficiency. These healthcare facilities support spina bifida in-utero by ensuring access to evidence-based therapies, skilled medical professionals, and innovative treatment options, all of which improve healing outcomes and quality of life for patients. For example, the American Hospital Association, a US-based non-profit organization, reported that the total number of hospitals in the United States reached 6,120 in 2024, a rise from 6,093 hospitals in 2022. This growth in healthcare infrastructure is thus contributing to the development of the spina bifida in-utero market.

Companies operating in the spina bifida in-utero market are focusing on establishing innovative centers, such as surgery centers, that incorporate advanced imaging and minimally invasive techniques for fetal interventions. Surgery centers are specialized facilities where surgical procedures are performed on an outpatient basis, eliminating the need for hospital admission. For instance, in January 2025, Wadia Hospital, located in India, opened a center offering fetal surgery for open spina bifida. The facility integrates state-of-the-art surgical techniques and a multidisciplinary approach to enable early intervention, which can reduce complications and improve long-term outcomes for infants affected by the condition. The center emphasizes surgical precision and high-quality patient care, offering hope for families dealing with the challenges of open spina bifida.

In March 2024, Lilavati Hospital, an India-based multi-specialty healthcare institution, formed a partnership with the Medical University of Silesia. This collaboration aims to establish a fetal surgery department to provide advanced in-utero treatment for birth defects, including spina bifida. The Medical University of Silesia, located in Poland, is known for its expertise in fetal surgery techniques and in-utero treatments for various conditions.

Major players in the spina bifida in-utero market are Mayo Clinic, GE HealthCare, UC San Francisco, Children's Health, Memorial Hermann Health System, Oregon Health & Science University, Seattle Children's, Texas Children's, Children's Hospital of Philadelphia, UW Health, UC Davis, UCSF Health, Burjeel Hospital, UT Physicians, Thieme Group, Riley Children's Health, Yale Medicine, Focused Ultrasound Foundation, Petals Health, Brown University Health.

North America was the largest region in the spina bifida in utero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spina bifida in-utero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spina bifida in-utero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spina bifida in-utero market consists of revenues earned by entities providing services such as physical therapy planning, genetic counseling, and multidisciplinary team support. The market value includes the value of related goods sold by the service provider or included within the service offering. The spina bifida in-utero market also includes sales of sales of anesthesia and maternal support equipment, fetal monitoring devices, and biodegradable adhesives and sealants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spina Bifida In-Utero Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on spina bifida in-utero market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for spina bifida in-utero ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spina bifida in-utero market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Myelomeningocele; Meningocele; Occulta
• 2) By Diagnosis: Ultrasound; Magnetic Resonance Imaging (MRI); Amniocentesis
• 3) By Treatment: Surgery; Postnatal Surgery; Medication Management
• 4) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
• Sub Segments:
• 1) By Myelomeningocele Type: Open Myelomeningocele; Closed Myelomeningocele; Lumbosacral Myelomeningocele; Thoracic Myelomeningocele; Cervical Myelomeningocele
• 2) By Meningocele Type: Cranial Meningocele; Spinal Meningocele; Occipital Meningocele; Frontal Meningocele; Parietal Meningocele
• 3) By Occulta Type: Lumbosacral Spina Bifida Occulta; Sacral Spina Bifida Occulta; Isolated Spina Bifida Occulta; Complex Spina Bifida Occulta; Tethered Cord Syndrome Associated Occulta
• Companies Mentioned: Mayo Clinic; GE HealthCare; UC San Francisco; Children's Health; Memorial Hermann Health System
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Spina Bifida In-Utero Market Characteristics

3. Spina Bifida In-Utero Market Trends And Strategies

4. Spina Bifida In-Utero Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Spina Bifida In-Utero Growth Analysis And Strategic Analysis Framework

• 5.1. Global Spina Bifida In-Utero PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Spina Bifida In-Utero Market Growth Rate Analysis
• 5.4. Global Spina Bifida In-Utero Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Spina Bifida In-Utero Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Spina Bifida In-Utero Total Addressable Market (TAM)

6. Spina Bifida In-Utero Market Segmentation

• 6.1. Global Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Myelomeningocele
• Meningocele
• Occulta
• 6.2. Global Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound
• Magnetic Resonance Imaging (MRI)
• Amniocentesis
• 6.3. Global Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Postnatal Surgery
• Medication Management
• 6.4. Global Spina Bifida In-Utero Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• 6.5. Global Spina Bifida In-Utero Market, Sub-Segmentation Of Myelomeningocele Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open Myelomeningocele
• Closed Myelomeningocele
• Lumbosacral Myelomeningocele
• Thoracic Myelomeningocele
• Cervical Myelomeningocele
• 6.6. Global Spina Bifida In-Utero Market, Sub-Segmentation Of Meningocele Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cranial Meningocele
• Spinal Meningocele
• Occipital Meningocele
• Frontal Meningocele
• Parietal Meningocele
• 6.7. Global Spina Bifida In-Utero Market, Sub-Segmentation Of Occulta Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lumbosacral Spina Bifida Occulta
• Sacral Spina Bifida Occulta
• Isolated Spina Bifida Occulta
• Complex Spina Bifida Occulta
• Tethered Cord Syndrome Associated Occulta

7. Spina Bifida In-Utero Market Regional And Country Analysis

• 7.1. Global Spina Bifida In-Utero Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Spina Bifida In-Utero Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Spina Bifida In-Utero Market

• 8.1. Asia-Pacific Spina Bifida In-Utero Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Spina Bifida In-Utero Market

• 9.1. China Spina Bifida In-Utero Market Overview
• 9.2. China Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Spina Bifida In-Utero Market

• 10.1. India Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Spina Bifida In-Utero Market

• 11.1. Japan Spina Bifida In-Utero Market Overview
• 11.2. Japan Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Spina Bifida In-Utero Market

• 12.1. Australia Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Spina Bifida In-Utero Market

• 13.1. Indonesia Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Spina Bifida In-Utero Market

• 14.1. South Korea Spina Bifida In-Utero Market Overview
• 14.2. South Korea Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Spina Bifida In-Utero Market

• 15.1. Western Europe Spina Bifida In-Utero Market Overview
• 15.2. Western Europe Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Spina Bifida In-Utero Market

• 16.1. UK Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Spina Bifida In-Utero Market

• 17.1. Germany Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Spina Bifida In-Utero Market

• 18.1. France Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Spina Bifida In-Utero Market

• 19.1. Italy Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Spina Bifida In-Utero Market

• 20.1. Spain Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Spina Bifida In-Utero Market

• 21.1. Eastern Europe Spina Bifida In-Utero Market Overview
• 21.2. Eastern Europe Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Spina Bifida In-Utero Market

• 22.1. Russia Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Spina Bifida In-Utero Market

• 23.1. North America Spina Bifida In-Utero Market Overview
• 23.2. North America Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Spina Bifida In-Utero Market

• 24.1. USA Spina Bifida In-Utero Market Overview
• 24.2. USA Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Spina Bifida In-Utero Market

• 25.1. Canada Spina Bifida In-Utero Market Overview
• 25.2. Canada Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Spina Bifida In-Utero Market

• 26.1. South America Spina Bifida In-Utero Market Overview
• 26.2. South America Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Spina Bifida In-Utero Market

• 27.1. Brazil Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Spina Bifida In-Utero Market

• 28.1. Middle East Spina Bifida In-Utero Market Overview
• 28.2. Middle East Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Spina Bifida In-Utero Market

• 29.1. Africa Spina Bifida In-Utero Market Overview
• 29.2. Africa Spina Bifida In-Utero Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Spina Bifida In-Utero Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Spina Bifida In-Utero Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Spina Bifida In-Utero Market Competitive Landscape And Company Profiles

• 30.1. Spina Bifida In-Utero Market Competitive Landscape
• 30.2. Spina Bifida In-Utero Market Company Profiles
  • 30.2.1. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GE HealthCare Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. UC San Francisco Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Children's Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Memorial Hermann Health System Overview, Products and Services, Strategy and Financial Analysis

31. Spina Bifida In-Utero Market Other Major And Innovative Companies

• 31.1. Oregon Health & Science University
• 31.2. Seattle Children's
• 31.3. Texas Children's
• 31.4. Children's Hospital of Philadelphia
• 31.5. UW Health
• 31.6. UC Davis
• 31.7. UCSF Health
• 31.8. Burjeel Hospital
• 31.9. UT Physicians
• 31.10. Thieme Group
• 31.11. Riley Children's Health
• 31.12. Yale Medicine
• 31.13. Focused Ultrasound Foundation
• 31.14. Petals Health
• 31.15. Brown University Health

32. Global Spina Bifida In-Utero Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Spina Bifida In-Utero Market

34. Recent Developments In The Spina Bifida In-Utero Market

35. Spina Bifida In-Utero Market High Potential Countries, Segments and Strategies

• 35.1 Spina Bifida In-Utero Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Spina Bifida In-Utero Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Spina Bifida In-Utero Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer